Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis Patients
Status:
Completed
Trial end date:
2021-01-18
Target enrollment:
Participant gender:
Summary
Is pneumococcal conjugate vaccine (which induces a T-dependent humoral response) more
efficient than pneumococcal polysaccharide vaccine (which induces a T-independent humoral
response) in RA patients treated with abatacept, biotherapy targeting T-cells? The
investigator propose to conduct a prospective, multicenter (11 centers), randomized,
open-label study.
The patients are going to be randomized in 2 groups: patients of the first group will be
vaccinated with the polysaccharide pneumococcal vaccine (Pneumo23®/Pneumovax®) whereas
patients of the second group will be vaccinated with conjugate pneumococcal vaccine
(Prevenar13®).